Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations

Authors Kibbe AH, Franko TS, Shah VM

Received 18 December 2017

Accepted for publication 1 March 2018

Published 30 April 2018 Volume 2018:14 Pages 779—782

DOI https://doi.org/10.2147/TCRM.S144564

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


AH Kibbe,1 TS Franko,2 VM Shah2

1Department of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, Wilkes-Barre, PA, USA; 2Department of Clinical Pharmacy, Nesbitt School of Pharmacy, Wilkes University, Wilkes-Barre, PA, USA

Abstract: This paper is an expert opinion in response to the development of abuse-deterrent immediate-release tablets containing oxycodone HCl. There is a potential impact, both positive and negative, of this type of dosage form on patients, those suffering from the disease of addiction, health care providers, and the cost of health care.

Keywords: non-metabolizable polymer, opioids, risk/benefit, IV abuse, nasal abuse

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]